Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability

被引:119
作者
Nishiyama, A
Yao, L
Fan, YY
Kyaw, M
Kataoka, N
Hashimoto, K
Nagai, Y
Nakamura, E
Yoshizumi, M
Shokoji, T
Kimura, S
Kiyomoto, H
Tsujioka, K
Kohno, M
Tamaki, T
Kajiya, F
Abe, Y
机构
[1] Kagawa Med Univ, Dept Pharmacol, Miki, Kagawa, Japan
[2] Kagawa Med Univ, Res Equipment Ctr, Miki, Kagawa, Japan
[3] Kagawa Med Univ, Dept Internal Med 2, Miki, Kagawa, Japan
[4] Univ Tokushima, Sch Med, Dept Pharmacol, Tokushima 770, Japan
[5] Kawasaki Med Sch, Dept Med Engn, Kurashiki, Okayama, Japan
[6] Kawasaki Med Sch, Dept Physiol, Kurashiki, Okayama, Japan
[7] Okayama Univ, Grad Sch Med & Dent, Dept Cardiovasc Physiol & Med Engn, Okayama 7008530, Japan
关键词
mineralocorticoids; aldosterone;
D O I
10.1161/01.HYP.0000154681.38944.9a
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We demonstrated recently that chronic administration of aldosterone to rats induces glomerular mesangial injury and activates mitogen-activated protein kinases including extracellular signal-regulated kinases 1/2 (ERK1/2). We also observed that the aldosterone-induced mesangial injury and ERK1/2 activation were prevented by treatment with a selective mineralocorticoid receptor (MR) antagonist, eplerenone, suggesting that the glomerular mesangium is a potential target for injuries induced by aldosterone via activation of MR. In the present study, we investigated whether MR is expressed in cultured rat mesangial cells (RMCs) and involved in aldosterone-induced RMC injury. MR expression and localization were evaluated by Western blotting analysis and fluorolabeling methods. Cell proliferation and micromechanical properties were determined by [H-3]-thymidine uptake measurements and a nanoindentation technique using an atomic force microscope cantilever, respectively. ERK1/2 activity was measured by Western blotting analysis with an anti-phospho-ERK1/2 antibody. Protein expression and immunostaining revealed that MR was abundant in the cytoplasm of RMCs. Aldosterone (1 to 100 nmol/L) dose-dependently activated ERK1/2 in RMCs with a peak at 10 minutes. Pretreatment with eplerenone (10 mu mol/L) significantly attenuated aldosterone-induced ERK1/2 phosphorylation. Aldosterone (100 nmol/L) treatment for 30 hours increased [H-3]-thymidine incorporation and decreased the elastic modulus, indicating cellular proliferative and deforming effects of aldosterone, respectively. These aldosterone-induced changes in cellular characteristics were prevented by pretreatment with eplerenone or an ERK (MEK) inhibitor, PD988059 (100 mu mol/L). The results indicate that aldosterone directly induces RMC proliferation and deformability through MR and ERK1/2 activation, which may contribute to the pathogenesis of glomerular mesangial injury.
引用
收藏
页码:710 / 716
页数:7
相关论文
共 37 条
[1]   Nongenomic effect of aldosterone on Na+,K+-adenosine triphosphatase in arterial vessels [J].
Alzamora, R ;
Marusic, ET ;
Gonzalez, M ;
Michea, L .
ENDOCRINOLOGY, 2003, 144 (04) :1266-1272
[2]   Rapid effects of aldosterone and spironolactone in the isolated working rat heart [J].
Barbato, JC ;
Mulrow, PJ ;
Shapiro, JI ;
Franco-Saenz, R .
HYPERTENSION, 2002, 40 (02) :130-135
[3]   Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats [J].
Blasi, ER ;
Rocha, R ;
Rudolph, AE ;
Blomme, EAG ;
Polly, ML ;
McMahon, EG .
KIDNEY INTERNATIONAL, 2003, 63 (05) :1791-1800
[4]   Rapid aldosterone actions: from the membrane to signaling cascades to gene transcription and physiological effects [J].
Boldyreff, B ;
Wehling, M .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 85 (2-5) :375-381
[5]   Aldosterone rapidly activates Src kinase in M-1 cells involving the mineralocorticoid receptor and HSP84 [J].
Braun, S ;
Lösel, R ;
Wehling, M ;
Boldyreff, B .
FEBS LETTERS, 2004, 570 (1-3) :69-72
[6]   Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo [J].
Brown, NJ ;
Nakamura, S ;
Ma, LJ ;
Nakamura, I ;
Donnert, E ;
Freeman, M ;
Vaughan, DE ;
Fogo, AB .
KIDNEY INTERNATIONAL, 2000, 58 (03) :1219-1227
[7]   Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. [J].
Chrysostomou, A ;
Becker, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :925-926
[8]  
Djelidi S, 2001, J AM SOC NEPHROL, V12, P1805, DOI 10.1681/ASN.V1291805
[9]   Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity [J].
Feria, I ;
Pichardo, I ;
Juárez, P ;
Ramírez, V ;
González, MA ;
Uribe, N ;
García-Torres, R ;
López-Casillas, F ;
Gamba, G ;
Bobadilla, NA .
KIDNEY INTERNATIONAL, 2003, 63 (01) :43-52
[10]   Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells [J].
Gekle, M ;
Freudinger, R ;
Mildenberger, S ;
Silbernagl, S .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 282 (04) :F669-F679